This startup develops electronic biosensors for molecular diagnostics, offering high-throughput solutions for drug discovery, drug delivery, and point-of-care applications. Their technology enables rapid and precise detection of molecular targets.
Funding
Funding not disclosed
Founders
Product
Problem
Current molecular diagnostic methods often suffer from limitations in throughput, cost, and accessibility, hindering advancements in drug discovery, drug delivery, and point-of-care applications. Traditional techniques can be time-consuming, require specialized equipment, and may not be suitable for rapid, high-volume screening.
Solution
Axiome is developing next-generation electronic biosensors designed to overcome these limitations by enabling low-cost, high-throughput molecular diagnostics. Their technology facilitates rapid and precise detection of molecular targets, accelerating drug discovery processes and enhancing the efficiency of drug delivery systems. By offering solutions suitable for point-of-care settings, Axiome aims to improve access to advanced diagnostics and monitoring.
Target Audience
The primary target audience includes pharmaceutical companies involved in drug discovery, research institutions focused on molecular diagnostics, and healthcare providers seeking point-of-care diagnostic solutions.
Features
- High-throughput electronic biosensors for rapid screening
- Low-cost design for accessible diagnostics
- Precise detection of molecular targets
- Applications in drug discovery, drug delivery, and point-of-care diagnostics